The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 25, 2024
Filed:
May. 29, 2019
Applicant:
Abcentra, Llc, Los Angeles, CA (US);
Inventors:
Bertrand C. Liang, San Diego, CA (US);
Stacey Ruiz, Beverly Hills, CA (US);
Christopher John Farina, Los Angeles, CA (US);
Assignee:
Abcentra, LLC, Los Angeles, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 17/06 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 9/00 (2006.01); A61K 31/203 (2006.01); A61K 31/573 (2006.01); A61K 31/593 (2006.01); A61K 35/04 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/775 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61P 17/06 (2018.01); C07K 16/18 (2013.01); A61K 9/0019 (2013.01); A61K 31/203 (2013.01); A61K 31/573 (2013.01); A61K 31/593 (2013.01); A61K 35/04 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 45/06 (2013.01); C07K 14/775 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01);
Abstract
Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.